On September 30, 2025, Opus Genetics, Inc. reported positive results from its ongoing Phase 1/2 clinical trial of OPGx-LCA5, an investigational treatment for Leber congenital amaurosis type 5, showing significant improvements in vision for pediatric participants, with an average visual acuity improvement of 0.3 logMAR and over 1 log unit improvement in cone sensitivity.